Hydrochlorothiazide And Losartan

Introduction Overview

Generic Name

hydrochlorothiazide and losartan

Brand Name

Hyzaar

Dosage Form

Oral tablet

Drug Class

Angiotensin II inhibitors with thiazides

Pharmacokinetics

Absorption:
Hydrochlorothiazide and losartan are administered orally as fixed-dose combination tablets. Hydrochlorothiazide is rapidly absorbed from the gastrointestinal tract with peak plasma concentrations typically occurring within 2 hours after administration. Losartan is also rapidly absorbed with peak plasma levels reached within 1 hour post-dose. The presence of food does not significantly affect the bioavailability of either agent, allowing administration with or without food. The bioavailability of losartan is approximately 33%, indicating moderate first-pass hepatic metabolism.

Distribution:
Hydrochlorothiazide shows a volume of distribution of 0.6 to 1.0 L/kg, indicating limited distribution primarily to extracellular fluid compartments. It binds minimally to plasma proteins (about 40%). Losartan exhibits moderate plasma protein binding at approximately 98%, mainly to albumin, contributing to its pharmacokinetic profile. The volume of distribution for losartan is about 34 L, reflecting distribution beyond the vascular compartment into tissues. Both drugs cross the placenta, and losartan is detected in breast milk, warranting caution in pregnant and breastfeeding patients.

Metabolism:
Hydrochlorothiazide undergoes minimal metabolism and is eliminated largely unchanged in the urine. In contrast, losartan undergoes extensive hepatic metabolism primarily via cytochrome P450 enzymes CYP2C9 and CYP3A4 to form an active carboxylic acid metabolite (EXP3174). This metabolite possesses a pharmacologic potency approximately 10 to 40 times greater than the parent compound and contributes significantly to the antihypertensive effect. Factors influencing hepatic metabolism, such as liver impairment or drug-drug interactions affecting CYP enzymes, can alter losartan's plasma levels and efficacy.

Elimination:
Hydrochlorothiazide is excreted primarily unchanged by the kidneys, with about 60-70% of the dose eliminated in urine. Its elimination half-life ranges from 6 to 15 hours, permitting once-daily dosing. Losartan has a terminal half-life of approximately 2 hours; however, its active metabolite has a longer half-life of 6 to 9 hours, allowing once-daily administration. Both losartan and its active metabolite are eliminated through biliary and renal pathways. Renal impairment can reduce clearance of hydrochlorothiazide, necessitating monitoring and dose adjustments. The combined elimination profiles support the combined preparation's once-daily dosing for sustained blood pressure control.

Dosage Forms

Available Dosage Forms:
Hyzaar is available in oral tablet form as a fixed-dose combination of hydrochlorothiazide and losartan potassium. The marketed tablets come in multiple dosage strengths to allow tailored antihypertensive therapy:
- Hydrochlorothiazide 12.5 mg and losartan 50 mg
- Hydrochlorothiazide 12.5 mg and losartan 100 mg
- Hydrochlorothiazide 25 mg and losartan 50 mg
- Hydrochlorothiazide 25 mg and losartan 100 mg

Dosages for Adults and Adolescents:
The usual dosage for treating hypertension in adults involves once-daily oral administration. Initial therapy generally starts with hydrochlorothiazide 12.5 mg and losartan 50 mg orally once daily. If blood pressure remains uncontrolled after about 3 weeks, the dose may be increased to hydrochlorothiazide 12.5 mg and losartan 100 mg once daily. Maximum dose regimens include hydrochlorothiazide 25 mg and losartan 100 mg once daily for patients requiring enhanced blood pressure control. In cases of severe hypertension, initial treatment may begin with hydrochlorothiazide 12.5 mg and losartan 50 mg with subsequent uptitration.

For hypertension with left ventricular hypertrophy, losartan monotherapy is initiated, with Hyzaar added as combination therapy if blood pressure is insufficiently controlled. Dosage is escalated progressively, typically from 12.5/50 mg to 25/100 mg daily as needed.

Specific Patient Populations:
Hyzaar dosing should be adjusted carefully in patients with renal impairment due to the renal elimination of hydrochlorothiazide. It is contraindicated for patients unable to produce urine. Caution and close monitoring are advised for patients with hepatic impairment because of losartan's hepatic metabolism. Hyzaar is contraindicated during pregnancy due to risks of fetal harm and should not be used during breastfeeding. Dose adjustments or alternative therapies should be considered for elderly patients and individuals with electrolyte imbalances or gout due to hydrochlorothiazide's effects.

Mechanism Of Action

Hyzaar is a fixed-dose combination drug consisting of hydrochlorothiazide, a thiazide diuretic, and losartan, an angiotensin II receptor antagonist (ARB). The combined mechanism targets complementary pathways involved in blood pressure regulation, producing a more effective antihypertensive action.

Hydrochlorothiazide acts primarily at the distal convoluted tubule in the nephron of the kidney. It inhibits the sodium-chloride symporter, reducing sodium and chloride reabsorption. This results in increased excretion of sodium, chloride, and water, leading to reduced plasma volume and decreased peripheral vascular resistance. The diuretic effect diminishes blood volume, thereby lowering cardiac output and systemic blood pressure. Over time, it also induces a reduction in peripheral vascular resistance possibly via direct relaxation of arteriolar smooth muscle.

Losartan selectively blocks the binding of angiotensin II to the angiotensin AT1 receptor subtype found in many tissues, including vascular smooth muscle and the adrenal gland. This blockade inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II. The result is vasodilation, reduced secretion of aldosterone (leading to decreased sodium and water retention), and attenuation of sympathetic nervous system activity. These effects collectively reduce systemic vascular resistance and blood pressure.

The pharmacological synergy between hydrochlorothiazide and losartan enhances antihypertensive efficacy. Hydrochlorothiazide reduces plasma volume and sodium load, countering the sodium retention that can upregulate the renin-angiotensin system. Losartan blocks angiotensin II–mediated vasoconstriction and aldosterone effects, which further helps prevent compensatory mechanisms that may resist diuretic therapy. Clinical studies demonstrate that the combination lowers blood pressure more effectively than either agent alone, with improvements in morbidity outcomes such as stroke risk reduction in specific populations. Additionally, losartan’s ability to block AT1 receptors while allowing AT2 receptor activation could confer cardiovascular and renal protective effects beyond blood pressure reduction.

Pharmacological Actions

Antihypertensive action through combined diuretic and angiotensin II receptor blockade mechanisms.
Diuretic effect via inhibition of sodium and chloride reabsorption in the distal renal tubules by hydrochlorothiazide, leading to reduced plasma volume.
Vasodilation resulting from losartan's blockade of angiotensin AT1 receptors, decreasing peripheral vascular resistance.
Reduction of aldosterone secretion by losartan, promoting further natriuresis and decreased fluid retention.
Prevention of sodium retention that typically accompanies diuretic therapy by losartan’s interruption of the renin-angiotensin-aldosterone system.
Decreased sympathetic nervous system activity secondary to AT1 receptor antagonism.
Reduction in stroke risk in hypertensive patients with left ventricular hypertrophy attributed primarily to losartan.
Long-lasting antihypertensive effect allowing once-daily dosing.
Minimal metabolic drug interactions due to losartan’s selective receptor antagonism and hydrochlorothiazide’s renal elimination.
Potential improvement of endothelial function by angiotensin receptor blockade.
Mild potassium-wasting effect from hydrochlorothiazide balanced by losartan’s potassium-sparing influence.
Reduction in cardiovascular remodeling through inhibition of angiotensin II effects.
Opposition to pathological hypertrophy via AT1 receptor blockade.
Renal protective effects in limiting progression of proteinuria and nephropathy via angiotensin receptor blockade.

Therapeutic Or Clinical Uses

Treatment of essential hypertension to lower elevated blood pressure.
Management of severe hypertension requiring prompt and effective blood pressure control.
Reduction of stroke risk in hypertensive patients with left ventricular hypertrophy, particularly non-Black populations.
Adjunctive therapy in hypertensive patients inadequately controlled on monotherapy with hydrochlorothiazide or losartan.
Combination therapy to enhance antihypertensive efficacy and reduce side effects related to high-dose monotherapy.
Improvement of cardiovascular outcomes by lowering hypertension-related morbidity and mortality.
Use in patients with volume overload where additional diuresis is beneficial.
Off-label consideration for patients with resistant hypertension under clinical discretion.
Clinical use in patients intolerant of ACE inhibitors due to cough, due to ARB component.
Potential renal protective effect in hypertensive patients at risk of nephropathy.
Treatment modality preferred in patients with mild to moderate renal impairment requiring blood pressure control.
Therapy choice for patients requiring combination therapy to improve compliance through fixed-dose formulation.
Utility in patients where monotherapy with either component is insufficient to achieve therapeutic goals.
Avoidance in initial therapy unless hypertension is severe and requires rapid control.

Side Or Adverse Effects

Dizziness and light-headedness, especially on standing, due to blood pressure lowering.
Electrolyte imbalances including hypokalemia resulting from hydrochlorothiazide diuretic action.
Hyperuricemia and possible gout flare due to decreased uric acid excretion by hydrochlorothiazide.
Back pain reported as a common adverse event.
Cold-like symptoms such as nasal congestion, sneezing, and sore throat.
Signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeats, numbness, or tingling.
Rare but serious muscle injury (rhabdomyolysis) with skeletal muscle breakdown potentially leading to kidney failure.
Allergic reactions including rash, hives, or angioedema, potentially involving skin or mucosal tissues.
Rare lupus-like syndrome exacerbation with symptoms such as joint pain and photosensitive rash.
Kidney function impairment manifested by reduced urine output, swelling, or rapid weight gain.
Hypotension especially following volume depletion, dehydration, or in elderly patients.
Photosensitivity reactions; increased risk of skin cancer with hydrochlorothiazide necessitating sun protection.
Gastrointestinal complaints including nausea or vomiting in some patients.
Potential elevation in blood sugar levels, caution in diabetic patients.
Fatigue or unusual tiredness associated with blood pressure lowering.

Precautions

Do not use during pregnancy due to potential for fetal injury or death, particularly in second and third trimesters.
Avoid use in patients unable to produce urine or with anuria.
Caution in patients with a history of lupus erythematosus, as medication may exacerbate symptoms.
Regular monitoring of blood pressure, electrolytes, renal function, and signs of electrolyte disturbances.
Use cautiously in patients with liver disease due to losartan hepatic metabolism.
Avoid use with aliskiren-containing drugs in patients with diabetes or renal impairment to prevent adverse outcomes.
Avoid potassium supplements or salt substitutes unless prescribed, to prevent hyperkalemia.
Monitor for signs of dehydration, especially in patients with vomiting, diarrhea, or excessive sweating.
Caution in patients with gout or predisposition to hyperuricemia due to hydrochlorothiazide effects.
Adjust dosage and monitor closely in elderly patients given possible increased sensitivity to hypotension.
Advise patients to avoid excessive sun exposure due to photosensitivity risk.
Review all concomitant medications to prevent significant drug interactions.
Patients should inform surgeons or anesthesiologists of use prior to surgery due to medication effects.
Breastfeeding is not recommended while taking Hyzaar due to potential drug transfer.
Emphasize adherence to therapy even if symptoms are not apparent for sustained blood pressure control.

Warnings

Hyzaar is contraindicated in pregnancy due to the risk of fetal toxicity or death.
Stop medication immediately and seek medical advice if pregnancy is detected during treatment.
Serious risk of kidney failure can occur with dehydration or significant blood pressure lowering.
Potential development of rhabdomyolysis, characterized by muscle pain, tenderness, weakness, fever, and dark urine.
Risk of severe hypotension in volume-depleted patients, elderly, or those with compromised renal function.
Use is contraindicated in patients unable to urinate.
Avoid concomitant use with aliskiren in diabetic or renal disease patients due to increased risk of adverse effects.
Electrolyte disturbances such as severe hyponatremia or hypokalemia may lead to life-threatening arrhythmias.
Photosensitizing effects of hydrochlorothiazide could increase risk of skin cancers with prolonged exposure.
Use caution with NSAIDs as they may reduce antihypertensive effects or impair renal function.
Possibility of angioedema or other allergic reactions requiring emergency treatment.
Patients may experience dizziness or fainting, increasing fall risk.
Discontinue if unexplained muscle symptoms or signs of systemic illness develop.
Avoid excessive alcohol intake which may potentiate hypotensive effects.
Monitor liver and kidney function during long-term therapy.

Contraindication

Known hypersensitivity to hydrochlorothiazide, losartan, or any component of the formulation.
Pregnancy, due to fetal toxicity, especially in second and third trimesters.
Inability to produce urine (anuria).
Concomitant use with aliskiren-containing medications in patients with diabetes or kidney disease.
History of angioedema related to previous ARB or ACE inhibitor therapy.
Severe hepatic impairment or cholestasis where losartan metabolism may be markedly impaired.
Hypersensitivity to sulfonamide-derived drugs (caution due to hydrochlorothiazide being a sulfonamide).
Severe electrolyte disturbances prior to correction (e.g., severe hyponatremia or hypokalemia).
Known bilateral renal artery stenosis posing risk of renal failure.
History of lupus erythematosus exacerbated by thiazide diuretics.
Use in breastfeeding women due to drug excretion in milk.
Concomitant use with potassium-sparing diuretics without monitoring risks.
Severe volume depletion or dehydration prior to initiation of therapy.
Severe hypotension or shock at baseline.
Known hypersensitivity to penicillin or sulfa drugs in context of hydrochlorothiazide cross-reactivity.

Drug Interactions

Concomitant use with potassium supplements or potassium-sparing diuretics may increase risk of hyperkalemia.
Nonsteroidal anti-inflammatory drugs (NSAIDs) including ibuprofen, naproxen, aspirin may reduce antihypertensive efficacy and impair renal function.
Aliskiren-containing antihypertensives are contraindicated in diabetes or renal impairment with Hyzaar.
Lithium toxicity risk is increased when used with hydrochlorothiazide due to decreased renal clearance.
Cholestyramine or colestipol may reduce absorption of Hyzaar; dosing should be separated by 4 to 6 hours.
Other antihypertensives may have additive blood pressure–lowering effects leading to hypotension.
Diuretics may increase risk of ototoxicity if combined with loop diuretics or aminoglycosides.
Drugs affecting cytochrome P450 enzymes (CYP2C9 and CYP3A4) may alter losartan metabolism and plasma levels.
Use with agents causing electrolyte imbalance increases risk of arrhythmias or muscle toxicity.
Concurrent use with corticosteroids may potentiate hypokalemia and hypertension.
Combination with other nephrotoxic drugs may enhance renal impairment risk.
Alcohol may potentiate hypotensive effects causing dizziness or syncope.
Salt substitutes containing potassium may lead to hyperkalemia when used with Hyzaar.
Antidiabetic agents may require dose adjustments due to alterations in blood glucose control.
Concomitant use with sympathomimetics may attenuate or oppose effect of Hyzaar.

Preparations Of The Drug

Oral tablets combining hydrochlorothiazide and losartan in fixed-dose strengths.
Available strengths include hydrochlorothiazide 12.5 mg with losartan 50 mg and 100 mg.
Higher dose tablets combine hydrochlorothiazide 25 mg with losartan 50 mg and 100 mg.
Formulated for once-daily oral administration.
Manufactured in film-coated tablets to improve stability and patient adherence.
Available as branded product Hyzaar and various generic formulations.
Packaged in blister packs or bottles to maintain drug integrity.
Storage recommended at room temperature, away from moisture and heat.
Provided with patient information leaflets detailing administration, precautions, and side effects.
Intended for prescription use only with dosing tailored by healthcare providers.